// App-Quantinova.ai

2292 : Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the ‘Use Via Early Access to Ixazomib’ (UVEA-IXA) Study

Researchers

Presenter

  • Heinz Ludwig

Principal Investigators

  • Evangelos Terpos

  • Mara-Victoria Mateos

  • Mario Boccadoro

  • Bhuvan Kishore

  • Karthik Ramasamy

  • Sylvie Fernandez

  • Fabio Ferri

  • Nawal Bent-Ennakhil

  • Athanasios Zomas

  • Franois Gavini

  • Roman Hajek

Medical Centers

  • Wilhelminen Cancer Research Institute, c/o Department of Medicine I, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

  • Departamento de Hematología, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain

  • Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • 7MediNeos Observational Research Modena Italy

  • Epidemiology and Outcome Research, MediNeos Observational Research, Modena, Italy

  • Medical Affairs, Europe & Canada, Takeda Pharmaceuticals International AG, Zurich, Switzerland

  • University Hospital, Ostrava, Czech Republic

Locations

  • Austria

  • Greece

  • Spain

  • Italy

  • United Kingdom

  • Switzerland

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • Ixazomib

Outcome

  • N/A

Study Design

  • Multinational

  • Prospective

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved